Veeva Systems (VEEV) Wells Fargo 21st Annual Healthcare Conference summary

Strategic vision and business overview

• Focused on building an industry cloud for life sciences, spanning R&D and commercial applications, data, and consulting.

• Recent years have seen a shift toward integrating an agentic AI layer, branded as Veeva Falcon, to automate and enhance core applications.

• AI strategy includes embedding Veeva Vault AI across all applications, aiming to improve efficiency and decision-making.

• Early adoption of AI products is strong, with increasing customer utilization and expansion among top pharma companies.

• Public benefit corporation status underpins a mission to advance the industry and serve broader stakeholder interests.

AI monetization and impact

• AI revenue is expected to be incremental to the previously announced $6 billion 2030 target, with monetization models evolving.

• Monetization approaches vary: Vault AI is consumption-based, while Falcon may use outcome-based or enterprise license models.

• AI delivers value through both cost reduction and accelerating time-to-market, especially in regulatory processes.

• Example: Falcon can expedite drug approval by automating regulatory responses, potentially generating millions in additional revenue for clients.

• Early feedback from customers is positive, with growing adoption and expansion in workflows.

Product portfolio dynamics and market expansion

• Mature products continue to contribute to growth, while newer products like EDC, Safety, and eCOA are ramping up.

• Transition to new products is underway, with expectations for broader adoption and market leadership over the next several years.

• Trial-based solutions through CROs represent a $1 billion opportunity, with early-stage traction and a focus on change management.

• Partnership with IQVIA enables integration and dual-sourcing of data, unlocking new sales opportunities and add-on products.

• Data products now work seamlessly with IQVIA, allowing customers to standardize on both providers.